The Global Erectile Dysfunction Drugs Market has been witnessing loss of patent protection in key geographies giving way to generic entry. The market is expected to witness a decline in its growth rate and post a CAGR of (4.47) percent during the period 2013-2018.
The patent expiry of major marketed products (Viagra, 2012) and weak drug pipeline are affecting the growth of the market. Eli Lily’s Cialis, which accounts for the second largest share in the Global Erectile Dysfunction Drugs Market, is expected to witness a decline in the market revenue owing to loss of patent exclusivity by 2017.
In addition, the patent for Bayer’s Levitra/Staxyn is set to expire by 2018 and is expected to contribute to deteriorating market revenue. Oral drugs belonging to the PDE 5 inhibitors class form the backbone of erectile dysfunction treatment.
Geographically, the Americas governs the Global Erectile Dysfunction Drugs Market because of the extension of patent exclusivity to 2020 for Pfizer’s Viagra in the US. The Global Erectile Dysfunction Drugs market is dominated by a few major players such as Apricus Biosciences, Bayer, Dong-A Socio, Eli Lilly, Pfizer, and Vivus. The competition in this market is expected to be characterized by strategic alliances and intensive M&As.
As it stands, the market is very competitive and is expected to become more competitive in the future. It is expected that avanafil, a PDE 5 inhibitor, will face rigid competition in the market. Avanafil is already available in the market in the form of Viagra, Cialis, and Levitra.
Thus, faced with intensifying competition and increasingly price sensitive markets, other manufacturers in the area of erectile dysfunction drugs are trying to differentiate their products in order to avoid price competition and to increase profits.
In 2013, the Americas dominated the market, where the major contribution was from the US, and this trend is expected to continue during the forecast period. The Americas was followed by the EMEA and APAC regions.
There is a vast opportunity for vendors in this market to expand in the APAC region. This is because of the increase in demand and availability of improved and advanced healthcare facilities in the region.
